Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac. The FTSE 100 pharmaceuticals giant said the case, originally scheduled for trial on 2 April, would now be dismissed.

It said it did not acknowledge any liability in this settlement, adding that it was committed to defending itself in all other Zantac cases.

Zantac was removed from shelves in April 2020 after the detection of an impurity called N-nitrosodimethylamine (NDMA), classified as a probable human carcinogen by the International Agency for Research on Cancer (IARC).

NDMA can form in certain drug products, including ranitidine-based medications like Zantac, under certain storage conditions or when exposed to high temperatures.

At 0812 GMT, shares in GSK were up 0.55% at 1,679p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Kefi shares pop on official launch of Tulu Kapi
(Sharecast News) - Kefi Gold and Copper officially launched the Tulu Kapi Gold Mines (TKGM) project in Ethiopia on Monday.
Sajid Javid reportedly in talks to join Shein ahead of London IPO
(Sharecast News) - Singapore-based fast fashion retailer Shein has reportedly approached the former chancellor Sajid Javid about joining the company ahead of its rumoured listing on the London Stock Exchange.
Bradda Head reaches settlement over fraudulent payment
(Sharecast News) - North America-focussed lithium developer Bradda Head announced on Monday that it has reached a settlement agreement over the fraudulent payment initially reported on 29 March 2022.
SDI Group set to end year in line with forecasts
(Sharecast News) - Scientific digital imaging, sensing and control technology company SDI Group said in a trading update on Monday that, pending its final accounts and audit, it expected to report revenue of £65.9m for the year, in line with current market expectations, but slightly down from £67.6m in 2023.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.